Ocular Therapeutix Inc Stock News

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Presentation Unknown Analyst Well, welcome Pravin. Great to have you here.

Ocular Therapeutix's value hinges on Axpaxli's Phase 3 success in Wet AMD, with recent protocol changes signaling management's confidence and bullish prospects. The company is well-capitalized through 2028, reducing financing risk ahead of pivotal data from two complementary trials that could yield a differentiated label. Superiority in SOL-1 would make Axpaxli a new standard of care, while non...

Ocular Therapeutix (OCUL -2.83%), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant widening in net loss due to increased research and marketing investments.

Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Pravin U. Dugel - Executive Chairman, President & CEO William S.

BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in July and August 2025.

The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience The new branding showcases the Company's innovative vision for the future and mission to redefine the retina experience

BEDFORD, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2025, taking place on June 21, 2025, in Las Vegas, NV.

BEDFORD, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a fully-integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor conferences in the second half of May 2025.